Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7% (18/49) and 67% (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0% (37/43) in cirrhotic patients and 86.2% (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liverrelated death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.
Abstract
Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7% (18/49) and 67% (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0% (37/43) in cirrhotic patients and 86.2% (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liverrelated death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.
참고문헌 (28)
- Mohd Hanafiah K, "Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)
- Shin HR, "Epidemiology of hepatitis C virus in Korea", Intervirology, 49, pp.18~22 (2006)
- Maasoumy B, "Natural history of acute and chronic hepatitis C", Best Pract Res Clin Gastroenterol, 26, pp.401~412 (2012)
- Perz JF, "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide", J Hepatol, 45, pp.529~538 (2006)
- Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
- Ng V, "Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C", Clin Gastroenterol Hepatol, 9, pp.923~930 (2011)
- Singal AG, "A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus", Clin Gastroenterol Hepatol, 8(e1), pp.280~288 (2010)
- Bruno S, "Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis", Hepatology, 51, pp.388~397 (2010)
- Lawitz E, "Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study", Lancet, 384, pp.1756~1765 (2014)
- Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection", N Engl J Med, 370, pp.1483~1493 (2014)
- Jin YJ, "Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naïve HCV patient in Korean population", BMC Gastroenterol, 13, pp.74~ (2013)
- Nae Yun Heo, "High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice", Clinical and Molecular Hepatology, 19(1), pp.60~69 (2013), 대한간학회[DOI]
- George SL, "Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year followup of 150 patients", Hepatology, 49, pp.729~738 (2009)
- Batts KP, "Chronic hepatitis: an update on terminology and reporting", Am J Surg Pathol, 19, pp.1409~1417 (1995)
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- European Association for Study of Liver, "EASL Clinical Practice Guidelines: management of hepatitis C virus infection", J Hepatol, 60, pp.392~420 (2014)
- Di Marco V, "Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial", J Hepatol, 47, pp.484~491 (2007)
- Giannini EG, "Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension", J Intern Med, 266, pp.537~546 (2009)
- Syed E, "Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis", Scand J Gastroenterol, 43, pp.1378~1386 (2008)
- 김경훈, "Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis", Clinical and Molecular Hepatology, 17(3), pp.220~225 (2011), 대한간학회
- 정홍렬, "간경변증을 동반한 만성 C형간염 환자에서 페그인터페론과 리바비린 병합요법의 치료 효과와 안전성", Clinical and Molecular Hepatology, 16(1), pp.38~48 (2010), 대한간학회
- Hadziyannis SJ, "Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
- McHutchison JG, "Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C", Gastroenterology, 123, pp.1061~1069 (2002)
- McHutchison JG, "Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection", N Engl J Med, 361, pp.580~593 (2009)
- Rumi MG, "Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C", Gastroenterology, 138, pp.108~115 (2010)
- Ascione A, "Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection", Gastroenterology, 138, pp.116~122 (2010)
- Backus LI, "A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C", Clin Gastroenterol Hepatol, 9(e1), pp.509~516 (2011)